Bli medlem
Bli medlem

Du är här


PCI Biotech: Mandatory notification of trade - Share option program

Lysaker, 20 April 2015
In accordance with the authorization granted by the Annual General Meeting
13thMay 2014, the Board of Directors of PCI Biotech Holding ASA has awarded a
total of 93,500 options to key employees. Each option gives the right to
subscribe for or acquire one share per option (after PCI Biotech Holding
ASA's choice), at a strike price of NOK 12.53, equal to the volume weighted
average price (VWAP) for the last 5 days of trade prior to the grant date.
The options can be exercised with 1/3 of the options after one year, further
1/3 after two years and the last third after three years. The options are
lapsing in Q3 2020.

Of these options, 20,000 options were allotted to Ronny Skuggedal, CFO. After
the allocation, Ronny Skuggedal holds a total portfolio of 60,000 unexercised
options and 0 shares.

For more information, please contact:
Per Walday, CEO

Mobile: 917 93 429

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.